Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer
Open Access
- 27 August 2021
- journal article
- research article
- Published by International Scientific Information, Inc. in The American Journal of Case Reports
- Vol. 22, e933396-1-e933396-4
- https://doi.org/10.12659/ajcr.933396
Abstract
Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer - Article abstract #933396Keywords
This publication has 15 references indexed in Scilit:
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCThe New England Journal of Medicine, 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline SummaryJournal of Oncology Practice, 2018
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-AnalysisFrontiers in Pharmacology, 2017
- Non‐specific pleuritis in patients with active malignancyRespirology, 2017
- Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatmentAnnals of Oncology, 2017
- Nivolumab-Induced Granulomatous Inflammation of the PleuraJournal of Thoracic Oncology, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two casesJournal for ImmunoTherapy of Cancer, 2016
- Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010Thorax, 2010